132 related articles for article (PubMed ID: 10341360)
1. Therapeutic aspects of polymorphic epithelial mucin in adenocarcinoma.
Miles DW; Taylor-Papadimitriou J
Pharmacol Ther; 1999 Apr; 82(1):97-106. PubMed ID: 10341360
[TBL] [Abstract][Full Text] [Related]
2. Mucin based breast cancer vaccines.
Miles DW; Taylor-Papadimitriou J
Expert Opin Investig Drugs; 1998 Nov; 7(11):1865-77. PubMed ID: 15991935
[TBL] [Abstract][Full Text] [Related]
3. Tecemotide: an antigen-specific cancer immunotherapy.
Wurz GT; Kao CJ; Wolf M; DeGregorio MW
Hum Vaccin Immunother; 2014; 10(11):3383-93. PubMed ID: 25483673
[TBL] [Abstract][Full Text] [Related]
4. Increased immunogenicity of tumor-associated antigen, mucin 1, engineered to express alpha-gal epitopes: a novel approach to immunotherapy in pancreatic cancer.
Deguchi T; Tanemura M; Miyoshi E; Nagano H; Machida T; Ohmura Y; Kobayashi S; Marubashi S; Eguchi H; Takeda Y; Ito T; Mori M; Doki Y; Sawa Y
Cancer Res; 2010 Jul; 70(13):5259-69. PubMed ID: 20530670
[TBL] [Abstract][Full Text] [Related]
5. Human MUC1 mucin: a multifaceted glycoprotein.
von Mensdorff-Pouilly S; Snijdewint FG; Verstraeten AA; Verheijen RH; Kenemans P
Int J Biol Markers; 2000; 15(4):343-56. PubMed ID: 11192832
[TBL] [Abstract][Full Text] [Related]
6. MUC1 and cancer.
Taylor-Papadimitriou J; Burchell J; Miles DW; Dalziel M
Biochim Biophys Acta; 1999 Oct; 1455(2-3):301-13. PubMed ID: 10571020
[TBL] [Abstract][Full Text] [Related]
7. MUC1 isoform specific monoclonal antibody 6E6/2 detects preferential expression of the novel MUC1/Y protein in breast and ovarian cancer.
Hartman M; Baruch A; Ron I; Aderet Y; Yoeli M; Sagi-Assif O; Greenstein S; Stadler Y; Weiss M; Harness E; Yaakubovits M; Keydar I; Smorodinsky NI; Wreschner DH
Int J Cancer; 1999 Jul; 82(2):256-67. PubMed ID: 10389761
[TBL] [Abstract][Full Text] [Related]
8. Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer.
Rochlitz C; Figlin R; Squiban P; Salzberg M; Pless M; Herrmann R; Tartour E; Zhao Y; Bizouarne N; Baudin M; Acres B
J Gene Med; 2003 Aug; 5(8):690-9. PubMed ID: 12898638
[TBL] [Abstract][Full Text] [Related]
9. Reduced Breast Tumor Growth after Immunization with a Tumor-Restricted MUC1 Glycopeptide Conjugated to Tetanus Toxoid.
Stergiou N; Gaidzik N; Heimes AS; Dietzen S; Besenius P; Jäkel J; Brenner W; Schmidt M; Kunz H; Schmitt E
Cancer Immunol Res; 2019 Jan; 7(1):113-122. PubMed ID: 30413430
[TBL] [Abstract][Full Text] [Related]
10. Definition of MHC-restricted CTL epitopes from non-variable number of tandem repeat sequence of MUC1.
Pietersz GA; Li W; Osinski C; Apostolopoulos V; McKenzie IF
Vaccine; 2000 Apr; 18(19):2059-71. PubMed ID: 10706970
[TBL] [Abstract][Full Text] [Related]
11. Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin.
von Mensdorff-Pouilly S; Verstraeten AA; Kenemans P; Snijdewint FG; Kok A; Van Kamp GJ; Paul MA; Van Diest PJ; Meijer S; Hilgers J
J Clin Oncol; 2000 Feb; 18(3):574-83. PubMed ID: 10653872
[TBL] [Abstract][Full Text] [Related]
12. T cells recognize PD(N/T)R motif common in a variable number of tandem repeat and degenerate repeat sequences of MUC1.
Pisarev VM; Kinarsky L; Caffrey T; Hanisch FG; Sanderson S; Hollingsworth MA; Sherman S
Int Immunopharmacol; 2005 Feb; 5(2):315-30. PubMed ID: 15652762
[TBL] [Abstract][Full Text] [Related]
13. Design of a MUC1-based cancer vaccine.
Hanisch FG
Biochem Soc Trans; 2005 Aug; 33(Pt 4):705-8. PubMed ID: 16042579
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of a Tripartite Cell Penetrating Peptide Containing a MUC1 Variable Number of Tandem Repeat (VNTR) and A T Helper Epitope.
Brooks N; Hsu J; Esparon S; Pouniotis D; Pietersz GA
Molecules; 2018 Sep; 23(9):. PubMed ID: 30200528
[TBL] [Abstract][Full Text] [Related]
15. Cell surface-associated anti-MUC1-derived signal peptide antibodies: implications for cancer diagnostics and therapy.
Kovjazin R; Horn G; Smorodinsky NI; Shapira MY; Carmon L
PLoS One; 2014; 9(1):e85400. PubMed ID: 24416403
[TBL] [Abstract][Full Text] [Related]
16. Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835].
Apostolopoulos V; Pietersz GA; Tsibanis A; Tsikkinis A; Drakaki H; Loveland BE; Piddlesden SJ; Plebanski M; Pouniotis DS; Alexis MN; McKenzie IF; Vassilaros S
Breast Cancer Res; 2006; 8(3):R27. PubMed ID: 16776849
[TBL] [Abstract][Full Text] [Related]
17. Role of transmembrane glycoprotein mucin 1 (MUC1) in various types of colorectal cancer and therapies: Current research status and updates.
Guo M; You C; Dou J
Biomed Pharmacother; 2018 Nov; 107():1318-1325. PubMed ID: 30257347
[TBL] [Abstract][Full Text] [Related]
18. Antibody-dependent cell-mediated cytotoxicity can be induced by MUC1 peptide vaccination of breast cancer patients.
Snijdewint FG; von Mensdorff-Pouilly S; Karuntu-Wanamarta AH; Verstraeten AA; Livingston PO; Hilgers J; Kenemans P
Int J Cancer; 2001 Jul; 93(1):97-106. PubMed ID: 11391628
[TBL] [Abstract][Full Text] [Related]
19. Human single-chain Fv antibodies to MUC1 core peptide selected from phage display libraries recognize unique epitopes and predominantly bind adenocarcinoma.
Henderikx P; Kandilogiannaki M; Petrarca C; von Mensdorff-Pouilly S; Hilgers JH; Krambovitis E; Arends JW; Hoogenboom HR
Cancer Res; 1998 Oct; 58(19):4324-32. PubMed ID: 9766660
[TBL] [Abstract][Full Text] [Related]
20. Immunization with a vaccine that combines the expression of MUC1 and B7 co-stimulatory molecules prolongs the survival of mice and delays the appearance of mouse mammary tumors.
Vasilevko V; Ghochikyan A; Sadzikava N; Petrushina I; Tran M; Cohen EP; Kesslak PJ; Cribbs DH; Nicolson GL; Agadjanyan MG
Clin Exp Metastasis; 2003; 20(6):489-98. PubMed ID: 14598882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
